The Scientific business of Thomson Reuters (formerly Thomson Scientific) has announced the launch of a new biomarkers report - 'Establishing the Standards in Biomarker Research.' The report gives a detailed introduction to the world of biomarkers, an overview of the regulatory context surrounding them, and highlights ongoing biomarker research in some of the world's leading Pharma companies.
Thomson Reuters has chosen to highlight advances in biomarker research because of its capacity to change the way Pharma companies do business. Biomarkers which are blood-based tests, gene sequences or mutations, mRNA expression profiles or tissue proteins, provide unparalleled evidence of the state of an organism, or indicate normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention.
The new Thomson Reuters biomarker report suggests that the disease areas at the forefront of the drive to discover new biomarkers are cancer, cardiology, neurology, and metabolic, autoimmune and inflammatory diseases. However, although biomarkers represent the future of drug development, Thomson Reuters analysis has found broad differences in the Pharma industry's approach to them. Some innovators have important biomarker research projects progressing, while many others have yet to attempt any research at all.
The Scientific business of Thomson Reuters provides information and knowledge to accelerate research, discovery and innovation. Its authoritative, accurate and timely information is essential for drug companies to discover new drugs and get them to market faster; researchers to find relevant papers and know what's newly published in their subject; and businesses to optimise their intellectual property and find competitive intelligence.
More News in this Theme
